Krahn M, Detsky A S
Department of Health Administration, University of Toronto, Ontario, Canada.
Med Decis Making. 1993 Jan-Mar;13(1):4-20. doi: 10.1177/0272989X9301300103.
This paper examines the economic attractiveness of universal vaccination of infants with hepatitis B virus (HBV) vaccine by calculating the incremental cost-effectiveness of this strategy when compared with the currently recommended strategy of screening all pregnant women and vaccinating only infants born to HBsAg+ mothers. A decision-analytic model involving a Markov process to model the long-term sequelae of HBV infection was constructed to estimate the expected costs and life expectancies for a cohort of newborns under two strategies: the current screening policy (SELECTIVE), which involves active and passive vaccination of infants born to carrier mothers, and a policy that combines the current screening strategy (including active and passive vaccination of infants born to carriers) with active vaccination alone for children of non-carriers (UNIVERSAL). A hypothetical cohort of children born in either Canada or the United States in 1991 was examined. Cost estimates were derived for Ontario. From a societal perspective, the incremental cost required to achieve one extra life year was found to be $30,347, comparable to the cost-effectiveness of other health care strategies commonly used in North America. The result is sensitive to the duration of vaccine effectiveness and particularly to the price of the vaccine. Universal vaccination results in net cost saving at a vaccine price of approximately $7 per dose, from a societal perspective. It is concluded that universal vaccination against HBV in infancy is economically attractive, comparable in cost-effectiveness to existing health care interventions. Lower vaccine prices would substantially improve the attractiveness of such a program. Implementation of universal vaccination should be considered in North America, contingent on vaccine price reduction. A monitoring program to ensure the long-term efficacy of the vaccine should be part of such a program.
本文通过计算与目前推荐的对所有孕妇进行筛查并仅对乙肝表面抗原阳性(HBsAg+)母亲所生婴儿进行疫苗接种的策略相比,普遍为婴儿接种乙肝病毒(HBV)疫苗策略的增量成本效益,来研究该策略的经济吸引力。构建了一个涉及马尔可夫过程以模拟HBV感染长期后遗症的决策分析模型,来估计在两种策略下一组新生儿的预期成本和预期寿命:当前的筛查政策(选择性策略),即对携带母亲所生婴儿进行主动和被动疫苗接种;以及一种将当前筛查策略(包括对携带母亲所生婴儿进行主动和被动疫苗接种)与仅对非携带者儿童进行主动疫苗接种相结合的政策(普遍策略)。研究了1991年在加拿大或美国出生的一组假设儿童。成本估计源自安大略省。从社会角度来看,每多获得一个生命年所需的增量成本为30,347美元,与北美常用的其他医疗保健策略的成本效益相当。结果对疫苗效力持续时间敏感,尤其对疫苗价格敏感。从社会角度来看,当疫苗价格约为每剂7美元时,普遍接种疫苗会带来净成本节省。得出的结论是,婴儿期普遍接种乙肝疫苗在经济上具有吸引力,其成本效益与现有的医疗保健干预措施相当。更低的疫苗价格将大幅提高此类项目的吸引力。在北美应考虑实施普遍接种疫苗,但前提是疫苗价格降低。确保疫苗长期效力的监测项目应成为此类项目的一部分。